<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/F34AC300-EA0B-49AC-9DE8-DF4287E54B4F"><gtr:id>F34AC300-EA0B-49AC-9DE8-DF4287E54B4F</gtr:id><gtr:name>The Garvan Institute for Medical Research</gtr:name></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/AB7C0822-BBCB-4C61-85EC-5D13C7A31759"><gtr:id>AB7C0822-BBCB-4C61-85EC-5D13C7A31759</gtr:id><gtr:name>MRC Laboratory of Molecular Biology</gtr:name><gtr:address><gtr:line1>Hills Road</gtr:line1><gtr:line4>Cambridge</gtr:line4><gtr:postCode>CB2 2QH</gtr:postCode><gtr:region>East of England</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/AB7C0822-BBCB-4C61-85EC-5D13C7A31759"><gtr:id>AB7C0822-BBCB-4C61-85EC-5D13C7A31759</gtr:id><gtr:name>MRC Laboratory of Molecular Biology</gtr:name><gtr:address><gtr:line1>Hills Road</gtr:line1><gtr:line4>Cambridge</gtr:line4><gtr:postCode>CB2 2QH</gtr:postCode><gtr:region>East of England</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/F34AC300-EA0B-49AC-9DE8-DF4287E54B4F"><gtr:id>F34AC300-EA0B-49AC-9DE8-DF4287E54B4F</gtr:id><gtr:name>The Garvan Institute for Medical Research</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/6EA95D06-4D9E-4D93-AEA5-67C36D17F060"><gtr:id>6EA95D06-4D9E-4D93-AEA5-67C36D17F060</gtr:id><gtr:firstName>Greg</gtr:firstName><gtr:surname>Winter</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=MC_U105115240"><gtr:id>CD200D83-6045-49AA-92AB-D691C8C98FFA</gtr:id><gtr:title>Evolution and protein engineering</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Intramural</gtr:grantCategory><gtr:grantReference>MC_U105115240</gtr:grantReference><gtr:abstractText>The origins of proteins are buried in the mists of time but comparisons of their gene sequences and/or 3 D protein structures can help us understand how they have evolved. As proteins close in evolution often have similar functions, this can help to make sense of the large amounts of DNA sequence information emerging from the Genome projects (for example to identify target proteins for therapeutic drugs). We propose to add a further dimension to existing approaches; to harness the power of evolution itself and to evolve proteins in the test-tube. We anticipate that this will help to understand how proteins evolved, to identify hidden relationships between modern proteins, and to endow modern proteins with novel functions, for example as antibodies or vaccines.</gtr:abstractText><gtr:technicalSummary>We will harness the power of phage selection technologies to provide insights into the evolution of proteins and their biophysical properties, and to the creation of novel proteins. More specifically, we will combine repertoires of gene fragments and use methods of selection to identify those with folded surfaces that retain features of the parent domains. We will use these combinatorial proteins as immunogens to focus the antibody response against a single epitope of the parent protein; this may have application in the development of vaccines targeted against self-antigens or the neutralizing epitopes of viruses. We will also develop the use of selection methods as a genomic tool to identify folded domains in sequences of the E. coli genome. Not only should this greatly facilitate the systematic assignment of sequences from whole genomes to families of known structures, but also pinpoint those encoding unknown architectures for structural determination. A key element of all the studies above will be the use of X-ray crystallography to determine the structures of domains, combinatorial proteins or antibody fragments.</gtr:technicalSummary><gtr:fund><gtr:end>2009-03-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>1984-04-01</gtr:start><gtr:type>EXPENDITURE_ACTUAL</gtr:type><gtr:valuePounds>1293742</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>The Garvan Institute for Medical Research</gtr:collaboratingOrganisation><gtr:country>Australia, Commonwealth of</gtr:country><gtr:description>Garvan Collaboration</gtr:description><gtr:id>822402FF-2727-4F10-BC7D-3580FCFF582A</gtr:id><gtr:impact>Advanced understanding of role of gamma globulin in treatment of rhumatoid arthritis</gtr:impact><gtr:outcomeId>546394792d7ab9.55916128-1</gtr:outcomeId><gtr:partnerContribution>Hosting Pete Jones during secondment; testing of fractionation in various animal models</gtr:partnerContribution><gtr:piContribution>Provision of advice; secondment of Peter Jones for 3 months in 2008 to set up fractionation protocols for investigation of role of gamma globulin in diseases including rhumatoid arthritis</gtr:piContribution><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2008-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Australian media</gtr:description><gtr:form>A press release, press conference or response to a media enquiry/interview</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>9A4B463D-64D9-4077-89A5-174E499A919D</gtr:id><gtr:impact>Interviewed by ABC Radio and TV for programs on my work on antibody therapeutics

Not known</gtr:impact><gtr:outcomeId>FE2D6167D80</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Media (as a channel to the public)</gtr:primaryAudience><gtr:year>2008</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Japanese industrialists-Tokyo</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>E5A0580F-EF08-424D-A560-7E55D90C09EA</gtr:id><gtr:impact>Described antibody technologies to Japanese industrialists at British Embassy Tokyo

None yet</gtr:impact><gtr:outcomeId>4F66B335659</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2007,2008,2009</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>17400</gtr:amountPounds><gtr:country>Global</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Novartis Foundation Fellowship</gtr:description><gtr:end>2007-12-02</gtr:end><gtr:fundingOrg>Novartis</gtr:fundingOrg><gtr:id>83B94D7B-C940-40C8-8470-0D99E8B1C89F</gtr:id><gtr:outcomeId>EAF4D28497A0</gtr:outcomeId><gtr:sector>Private</gtr:sector><gtr:start>2007-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>18700</gtr:amountPounds><gtr:country>Switzerland, Swiss Confederation</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>SNSF Fellowship</gtr:description><gtr:end>2006-12-02</gtr:end><gtr:fundingOrg>Swiss National Science Foundation</gtr:fundingOrg><gtr:id>1E058689-573A-41A1-9878-65D8E9C3DDEE</gtr:id><gtr:outcomeId>5FE0EBE30CF0</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>2500</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>Medical Research Foundation</gtr:department><gtr:description>Jeantet Fellowship - Daniel Christ</gtr:description><gtr:end>2006-11-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>78E1C9AB-6D57-4CA4-8300-E9B2E7FA0408</gtr:id><gtr:outcomeId>118B7ED0E0E0</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2006-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>2500</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>Medical Research Foundation</gtr:department><gtr:description>Jeantet Fellowship - Heinis</gtr:description><gtr:end>2008-01-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>3AB11D7A-F18A-4D77-B6BA-A68F457102D4</gtr:id><gtr:outcomeId>03651DA50720</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2008-01-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs><gtr:intellectualPropertyOutput><gtr:description>The invention provides a method for preparing a library of transformed host cells said method comprising the steps of taking a library of closed circular DNA molecules; amplifying said library of closed circular DNA molecules through a rolling circle mechanism in the presence of a strand displacement polymerase to generate a library of linear concatamers; cleaving said linear concatamers to generate a library of linear DNA molecules; re-circularising said library of linear DNA molecules to generate a library of circular DNA molecules; and transforming said library of circular DNA molecules into host cells.</gtr:description><gtr:grantRef>MC_U105115240</gtr:grantRef><gtr:id>06CEF8E4-652E-4DCC-B7E8-E76F4F112E5C</gtr:id><gtr:impact>NA</gtr:impact><gtr:licensed>Commercial In Confidence</gtr:licensed><gtr:outcomeId>AD5ban8fRV7</gtr:outcomeId><gtr:patentId>WO2008012529</gtr:patentId><gtr:protection>Patent granted</gtr:protection><gtr:title>Method for Amplication of Ligation Reactions</gtr:title><gtr:yearProtectionGranted>2008</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput></gtr:intellectualPropertyOutputs><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs><gtr:productOutput><gtr:description>Antibody therapeutic against IL6 receptor developed by Chugai/Roche licensees of MRC invention of humanised antibodies, approved in Japan</gtr:description><gtr:id>8F7D2881-E90D-46BB-AF80-ADB27F24A4B4</gtr:id><gtr:impact>Treatment of rheumatoid arthritis</gtr:impact><gtr:outcomeId>E1C70360667</gtr:outcomeId><gtr:stage>Small-scale adoption</gtr:stage><gtr:status>Under active development/distribution</gtr:status><gtr:title>Actemra</gtr:title><gtr:type>Therapeutic Intervention - Drug</gtr:type><gtr:yearDevCompleted>2010</gtr:yearDevCompleted></gtr:productOutput><gtr:productOutput><gtr:description>Antibody therapeutic against cellular adhesion molecule alpha 4 integrin, developed by Biogen Idec and Elan, licensees of MRC invention of humanised antibodies, approved by US FDA</gtr:description><gtr:id>4E981A2D-A002-4B32-B924-AC3299E0A110</gtr:id><gtr:impact>Treatment of multiple sclerosis</gtr:impact><gtr:outcomeId>E95EC180CA1</gtr:outcomeId><gtr:stage>Small-scale adoption</gtr:stage><gtr:status>Under active development/distribution</gtr:status><gtr:title>Tysabri</gtr:title><gtr:type>Therapeutic Intervention - Drug</gtr:type><gtr:yearDevCompleted>2007</gtr:yearDevCompleted></gtr:productOutput><gtr:productOutput><gtr:description>Antibody therapeutic against IL6 receptor developed by Chugai/Roche licensees of MRC invention of humanised antibodies.</gtr:description><gtr:id>9C2D8625-B084-4453-8011-B00450FA69A1</gtr:id><gtr:impact>Treatment of systemic onset juvenile idiopathic arthritis</gtr:impact><gtr:outcomeId>BE0168B1FF2</gtr:outcomeId><gtr:stage>Market authorisation</gtr:stage><gtr:status>Under active development/distribution</gtr:status><gtr:title>Actemra</gtr:title><gtr:type>Therapeutic Intervention - Drug</gtr:type><gtr:yearDevCompleted>2010</gtr:yearDevCompleted></gtr:productOutput><gtr:productOutput><gtr:clinicalTrial>true</gtr:clinicalTrial><gtr:description>Antibody therapeutic against the target Blys developed by Human Genome Sciences and Cambridge Antibody Technology (licensees of MRC/Cambridge Antibody Technology inventions of combinatorial antibody libraries/phage display)</gtr:description><gtr:id>E1917609-4A98-4FCD-8B93-6B5E14969D6B</gtr:id><gtr:impact>First new treatment of systemic lupus erythematosis (SLE) for fifty years.</gtr:impact><gtr:outcomeId>DC171DC2039</gtr:outcomeId><gtr:stage>Market authorisation</gtr:stage><gtr:status>Under active development/distribution</gtr:status><gtr:title>Benlysta</gtr:title><gtr:type>Therapeutic Intervention - Drug</gtr:type><gtr:yearDevCompleted>2009</gtr:yearDevCompleted></gtr:productOutput><gtr:productOutput><gtr:description>Antibody therapeutic against VEGF developed by Genentech/Roche, licensees of MRC invention of humanised antibodies, approved in Japan</gtr:description><gtr:id>35614BD4-4038-4308-AC48-7CC083BB4FAD</gtr:id><gtr:impact>Treatment of wet age-related macular degeneration</gtr:impact><gtr:outcomeId>C40B5E236B8</gtr:outcomeId><gtr:stage>Small-scale adoption</gtr:stage><gtr:status>Under active development/distribution</gtr:status><gtr:title>Lucentis</gtr:title><gtr:type>Therapeutic Intervention - Drug</gtr:type><gtr:yearDevCompleted>2008</gtr:yearDevCompleted></gtr:productOutput><gtr:productOutput><gtr:description>Antibody therapeutic against IL-13 developed by Medimmune (licensees of MRC/Cambridge Antibody Technology inventions of combinatorial antibody libraries/phage display)</gtr:description><gtr:id>9CED79CD-3CB3-4D7B-A259-C17F13DE9D2D</gtr:id><gtr:impact>Safety data for treatment of asthma</gtr:impact><gtr:outcomeId>E2DD6E54E5D</gtr:outcomeId><gtr:stage>Late clinical evaluation</gtr:stage><gtr:status>Under active development/distribution</gtr:status><gtr:title>CAT-354</gtr:title><gtr:type>Therapeutic Intervention - Drug</gtr:type><gtr:yearDevCompleted>2010</gtr:yearDevCompleted></gtr:productOutput><gtr:productOutput><gtr:description>Antibody therapeutic against TNF alpha developed by Abbott and Cambridge Antibody Technology (licensees of MRC/Cambridge Antibody Technology inventions of combinatorial antibody libraries/phage display) approved by US FDA</gtr:description><gtr:id>5B67189A-726F-4B54-8170-A49F67B775F8</gtr:id><gtr:impact>Treatment of psoriasis</gtr:impact><gtr:outcomeId>EAFA88EDC07</gtr:outcomeId><gtr:stage>Market authorisation</gtr:stage><gtr:status>Under active development/distribution</gtr:status><gtr:title>Humira</gtr:title><gtr:type>Therapeutic Intervention - Drug</gtr:type><gtr:yearDevCompleted>2008</gtr:yearDevCompleted></gtr:productOutput><gtr:productOutput><gtr:description>Antibody therapeutic against IL-12/23 developed by Abbott and Cambridge Antibody Technology (licensees of MRC/Cambridge Antibody Technology inventions of combinatorial antibody libraries/phage display)</gtr:description><gtr:id>B89917C9-D438-4F42-8630-7A81FD831C67</gtr:id><gtr:impact>Treatment for psoriasis</gtr:impact><gtr:outcomeId>9195AE4D438</gtr:outcomeId><gtr:status>Under active development/distribution</gtr:status><gtr:title>ABT-874</gtr:title><gtr:type>Therapeutic Intervention - Drug</gtr:type><gtr:yearDevCompleted>2008</gtr:yearDevCompleted></gtr:productOutput><gtr:productOutput><gtr:description>Antibody therapeutic against TNF alpha developed by Abbott and Cambridge Antibody Technology (licensees of MRC/Cambridge Antibody Technology inventions of combinatorial antibody libraries/phage display) approved by US FDA</gtr:description><gtr:id>CAF5E61C-79F7-4791-B396-592C4168AC9D</gtr:id><gtr:impact>Treatment for ankylosing spondylitis</gtr:impact><gtr:outcomeId>ED3BEF34AC9</gtr:outcomeId><gtr:stage>Market authorisation</gtr:stage><gtr:status>Under active development/distribution</gtr:status><gtr:title>Humira</gtr:title><gtr:type>Therapeutic Intervention - Drug</gtr:type><gtr:yearDevCompleted>2006</gtr:yearDevCompleted></gtr:productOutput><gtr:productOutput><gtr:description>Antibody therapeutic against TNF alpha developed by Celltech/UBS licensees of MRC invention of humanised antibodies, approved by US FDA</gtr:description><gtr:id>A29B7506-A104-4141-8259-445757045270</gtr:id><gtr:impact>Treatment of Crohn's disease</gtr:impact><gtr:outcomeId>EC6F7F19307</gtr:outcomeId><gtr:stage>Market authorisation</gtr:stage><gtr:status>Under active development/distribution</gtr:status><gtr:title>Cimzia</gtr:title><gtr:type>Therapeutic Intervention - Drug</gtr:type><gtr:yearDevCompleted>2008</gtr:yearDevCompleted></gtr:productOutput><gtr:productOutput><gtr:description>Antibody therapeutic against complement system C5 developed by Alexion Pharmaceuticals, licensees of MRC invention of humanised antibodies, approved by US FDA</gtr:description><gtr:id>19B17718-D8E3-43A9-A06C-FC31BC78A127</gtr:id><gtr:impact>Treatment of paroxysmal nocturnal hemoglobinuria</gtr:impact><gtr:outcomeId>5E1A074B22E</gtr:outcomeId><gtr:stage>Late clinical evaluation</gtr:stage><gtr:status>Under active development/distribution</gtr:status><gtr:title>Soliris</gtr:title><gtr:type>Therapeutic Intervention - Drug</gtr:type><gtr:yearDevCompleted>2009</gtr:yearDevCompleted></gtr:productOutput><gtr:productOutput><gtr:clinicalTrial>true</gtr:clinicalTrial><gtr:description>Antibody therapeutic against Anthrax developed by Human Genome Sciences and Cambridge Antibody Technology (licensees of MRC/Cambridge Antibody Technology inventions of combinatorial antibody libraries/phage display)</gtr:description><gtr:id>611A8514-8245-4FE0-BF38-F34FCE08264F</gtr:id><gtr:impact>Stockpiled by US Government for treatment of anthrax infections</gtr:impact><gtr:outcomeId>E37BFD9D843</gtr:outcomeId><gtr:stage>Market authorisation</gtr:stage><gtr:status>Under active development/distribution</gtr:status><gtr:title>Abthrax</gtr:title><gtr:type>Therapeutic Intervention - Drug</gtr:type><gtr:yearDevCompleted>2009</gtr:yearDevCompleted></gtr:productOutput><gtr:productOutput><gtr:description>Antibody therapeutic against TNF alpha developed by Abbott and Cambridge Antibody Technology (licensees of MRC/Cambridge Antibody Technology inventions of combinatorial antibody libraries/phage display) approved by FDA</gtr:description><gtr:id>E074210B-8A91-4B16-9790-52C0D0F9804E</gtr:id><gtr:impact>Treatment of Crohn's disease</gtr:impact><gtr:outcomeId>5316C04CCC6</gtr:outcomeId><gtr:stage>Late clinical evaluation</gtr:stage><gtr:status>Under active development/distribution</gtr:status><gtr:title>Humira</gtr:title><gtr:type>Therapeutic Intervention - Drug</gtr:type><gtr:yearDevCompleted>2010</gtr:yearDevCompleted></gtr:productOutput></gtr:productOutputs><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>E0820651-BE1E-4399-8ED1-919FC152E475</gtr:id><gtr:title>Tapping diversity lost in transformations--in vitro amplification of ligation reactions.</gtr:title><gtr:parentPublicationTitle>Nucleic acids research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b7e9386539cfa09a9fb8182035f6df73"><gtr:id>b7e9386539cfa09a9fb8182035f6df73</gtr:id><gtr:otherNames>Christ D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0305-1048</gtr:issn><gtr:outcomeId>0C6F5FEE211</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>74C728C9-85A6-4C84-B6B8-D9AF4E0DB744</gtr:id><gtr:title>Identification of protein domains by shotgun proteolysis.</gtr:title><gtr:parentPublicationTitle>Journal of molecular biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b7e9386539cfa09a9fb8182035f6df73"><gtr:id>b7e9386539cfa09a9fb8182035f6df73</gtr:id><gtr:otherNames>Christ D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0022-2836</gtr:issn><gtr:outcomeId>4E2E9B9559E</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E6E6C9D0-E9BD-4730-8F90-A61812B60FBB</gtr:id><gtr:title>Mapping epitopes and antigenicity by site-directed masking.</gtr:title><gtr:parentPublicationTitle>Proceedings of the National Academy of Sciences of the United States of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7bf5f6be0609de7d8c15e2f4d95d697c"><gtr:id>7bf5f6be0609de7d8c15e2f4d95d697c</gtr:id><gtr:otherNames>Paus D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0027-8424</gtr:issn><gtr:outcomeId>79A287EBA80</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7C4CBA1E-561A-46B7-9A20-AD82C441592F</gtr:id><gtr:title>Thermodynamically stable aggregation-resistant antibody domains through directed evolution.</gtr:title><gtr:parentPublicationTitle>Journal of molecular biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1a9137c76ffb6addcb16d18cbd5582bf"><gtr:id>1a9137c76ffb6addcb16d18cbd5582bf</gtr:id><gtr:otherNames>Famm K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0022-2836</gtr:issn><gtr:outcomeId>5D5ECCBF4ED</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1506D93B-F20E-4658-9939-E2DB53CF486D</gtr:id><gtr:title>Beta-edge interactions in a pentadecameric human antibody V kappa domain.</gtr:title><gtr:parentPublicationTitle>Journal of molecular biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/413eff2f4a5d4faf73a5ac9ea92f6a17"><gtr:id>413eff2f4a5d4faf73a5ac9ea92f6a17</gtr:id><gtr:otherNames>James LC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0022-2836</gtr:issn><gtr:outcomeId>F620F867280</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F05E28FF-E443-4B54-A82F-2EE23636ADDF</gtr:id><gtr:title>Engineering aggregation-resistant proteins by directed evolution.</gtr:title><gtr:parentPublicationTitle>Protein engineering, design &amp; selection : PEDS</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1a9137c76ffb6addcb16d18cbd5582bf"><gtr:id>1a9137c76ffb6addcb16d18cbd5582bf</gtr:id><gtr:otherNames>Famm K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>1741-0126</gtr:issn><gtr:outcomeId>6BF86B56AE4</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>16366228-C90E-4A40-9504-3C304B67AE60</gtr:id><gtr:title>Repertoires of aggregation-resistant human antibody domains.</gtr:title><gtr:parentPublicationTitle>Protein engineering, design &amp; selection : PEDS</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b7e9386539cfa09a9fb8182035f6df73"><gtr:id>b7e9386539cfa09a9fb8182035f6df73</gtr:id><gtr:otherNames>Christ D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>1741-0126</gtr:issn><gtr:outcomeId>2F9A2339707</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CBA9E701-A6F0-40B3-837D-D2E2AE5BC746</gtr:id><gtr:title>Inhibition of papillomavirus protein function in cervical cancer cells by intrabody targeting.</gtr:title><gtr:parentPublicationTitle>Journal of molecular biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/67ce09e20d856408a7b59f5c51db18c8"><gtr:id>67ce09e20d856408a7b59f5c51db18c8</gtr:id><gtr:otherNames>Griffin H</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0022-2836</gtr:issn><gtr:outcomeId>2669A26C3DD</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C9E30AEE-8633-4D23-A131-8683BB4C897C</gtr:id><gtr:title>Bicyclic peptide inhibitor reveals large contact interface with a protease target.</gtr:title><gtr:parentPublicationTitle>ACS chemical biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/174dee143405fe184abf0ab29566459b"><gtr:id>174dee143405fe184abf0ab29566459b</gtr:id><gtr:otherNames>Angelini A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1554-8929</gtr:issn><gtr:outcomeId>56e05d40046f78.38204061</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>FCA2A085-953B-4710-A1CF-16B225DC07AC</gtr:id><gtr:title>Early protein evolution: building domains from ligand-binding polypeptide segments.</gtr:title><gtr:parentPublicationTitle>Journal of molecular biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4bb13db39d85c057894a6d408fef3f8b"><gtr:id>4bb13db39d85c057894a6d408fef3f8b</gtr:id><gtr:otherNames>Riechmann L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0022-2836</gtr:issn><gtr:outcomeId>D840B94E5B7</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>98E4C1F4-8955-4289-BF28-6D40AE1257B9</gtr:id><gtr:title>Development Of A Protease-Resistant Bicyclic Peptide Targeting Human Plasma Kallikrein</gtr:title><gtr:parentPublicationTitle>J Pept Sci</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/00d3fff2912e1599329bc4b60af86d44"><gtr:id>00d3fff2912e1599329bc4b60af86d44</gtr:id><gtr:otherNames>Bernard E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:outcomeId>56e06086ea9672.09032664</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8A392181-023C-49E7-B1B0-04A1CE3A1CE9</gtr:id><gtr:title>Phage-encoded combinatorial chemical libraries based on bicyclic peptides.</gtr:title><gtr:parentPublicationTitle>Nature chemical biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/33e60dc6b75273870ca983dfab206a64"><gtr:id>33e60dc6b75273870ca983dfab206a64</gtr:id><gtr:otherNames>Heinis C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1552-4450</gtr:issn><gtr:outcomeId>1B5A5F807F0</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">MC_U105115240</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>F3822669-BB5A-4BB4-BAE0-DCB9DE36E092</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Generic Health Relevance</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>CF950C9A-DB16-4E23-8AEB-94548777BCA1</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>1.1  Normal biological development and functioning</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>